Compositions and methods for treating depression

The present disclosure provides methods for treating major depressive disorder in a human patient, wherein the patient is identified as being positive as a biomarker feature. The methods comprise administering to a patient in need thereof an effective amount of atipram, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient is insufficiently responsive to other antidepressant therapy prior to treatment with atecatram. In other embodiments, the other antidepressant therapy includes a selective serotonin reuptake inhibitor (SSRI), a serotonin-noradrenaline reuptake inhibitor (SNRI), or a combination thereof. 本公开提供了用于治疗人类患者的重性抑郁障碍的方法，其中该患者被鉴定为生物标志物特征标识阳性。这些方法包括向有需要的患者施用有效量的阿替卡普兰(aticaprant)或其药学上可接受的盐。在一些实施方案中，在用阿替卡普兰治疗之前，该患者对其他抗抑郁药疗法的反应不足。在其他实施方案中，该其他抗抑郁药疗法包括选择性5-羟色胺再摄取抑制剂(SSRI)、5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)或它们的组合。